Venture Capital Investments by Big Pharma September 27, 2007

Agenda
3:00-3:30 PM Networking & Registration
3:30-5:00 PM Experts Panel
5:00-6:30 PM BBQ Networking Reception

2006 marked the highest level of investment since 2001. According to PricewaterhouseCoopers' MoneyTree Report, the Life Sciences sector (Biotechnology and Medical Devices industries, together) set the pace for investing in 2006 with $7.2 billion in 731 deals. For the year, Life Sciences accounted for 28% of all venture capital invested and seed and early stage deals accounted for 34% of the total deals done in 2006. However, today, traditional VCs are not the only ones making these investments as many "Big Pharma" have created their own Venture Capital Investments Divisions to invest in bio companies. Join an expert panel of the most active Big Pharma VCs at the BioCenter and discuss this new source of capital with a particular focus on the following 2 topics:
- Do's & Don'ts: How to approach and attract them?
- Pros & Cons: How are they different from regular VCs?

The roundtable discussion format is interactive and informal and intended to be a conversation more than a presentation. So bring your questions with you!

Panelists include: Janis C. Naeve, Ph.D., Amgen Ventures; S. Edward Torres, Principal, Lilly Ventures; Scott M. Iyama, Corporate Lawyer, Member of the Emerging Companies Group, Orrick, Herrington & Sutcliffe LLP...

About San Jose BioCenter:
The San Jose BioCenter features state of the art lab and business space, a brand new Chemistry Analytics Lab and world class business development services for high potential bioscience companies.
The goal of the San Jose BioCenter is to advance technology for societal benefit and to catalyze economic development for community growth.

COST & REGISTRATION:
Regular $40 | Partners' Network $30 | Members: Free | Door Registration: add $10.
http://www.acteva.com/booking.cfm?bevaid=132178

Official Website: http://www.sjbiocenter.com/ev_industry-roundtable-Q3.html